FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Oragenics, Inc Skyrockets Amid Entering Licensing Agreement with the National Research Council of Canada”
Oragenics, Inc (NYSE: OGEN) surged over 48% in premarket trading after the company entered into a licensing agreement with the National Research Council of Canada to pursue the rapid development of next-generation SARS-CoV-2 vaccines
The agreement provides Oragenics with antigen expression cell line technology capable of producing spike proteins within six to eight weeks of gene sequence definition, a timeline that will expedite the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical studies.
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, a vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on addressing supply-chain challenges, and offering more patient-friendly administration, such as intranasal. Its lantibiotics program features a novel class of antibiotics against infectious diseases that have developed resistance to commercial antibiotics.
For more information, please visit: Oragenics Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.